Lipodystrophy papers of the month

DECEMBER 2023

Clinical characteristics of patients with acquired partial lipodystrophy: a multicenter retrospective study

Magno et al.
J Clin Endocrinol Metal.
DOI: 10.1210/clinem/dgad700.
https://pubmed.ncbi.nlm.nih.gov/38061004/

The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B

Odinammadu et al.
Nucleus
DOI: 10.1080/19491034.2023.2288476.
https://pubmed.ncbi.nlm.nih.gov/38050983/

NOVEMBER 2023

Mineralcorticoid receptor antagonism prevents type 2 familial partial lipodystrophy brown adipocyte dysfunction

Schena et al.
Cells
DOI: 10.3390/cells12222586.
https://pubmed.ncbi.nlm.nih.gov/37998321/

Loss of phospholipase PLAAT3 causes a mixed lipodystrophic and neurological syndrome due to impaired PPARγ signaling

Schuermans et al.

Nat. Genet.
DOI: 10.1038/s41588-023-01535-3.
https://pubmed.ncbi.nlm.nih.gov/37919452/

Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain

Fernández-Pombo et al.
Front Endocrinol (Lausanne)
DOI: 10.3389/fendo.2023.1250203.
https://pubmed.ncbi.nlm.nih.gov/38034001/